For its first quarter, which ended on Sept. 30, the company reported that net sales of biomaterials products were $12.6 million, compared to $12.7 million in the comparable period last year.
Orthopedic sales, primarily of sports medicine and spine products, fell from $8.0 million to $6.4 million, and within that figure, net sales of spine products fell $1.0 million to $2.7 million.
Read the release on Kensey Nash’s quarterly sales.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
